Adage Capital Partners Gp, L.L.C. Crinetics Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $52.3 Billion
- Q2 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 201,048 shares of CRNX stock, worth $10.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
201,048
Previous 632,133
68.2%
Holding current value
$10.2 Million
Previous $29.6 Million
69.57%
% of portfolio
0.02%
Previous 0.06%
Shares
7 transactions
Others Institutions Holding CRNX
# of Institutions
244Shares Held
78.2MCall Options Held
268KPut Options Held
197K-
Black Rock Inc. New York, NY6.23MShares$316 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.11MShares$310 Million2.95% of portfolio
-
Wellington Management Group LLP Boston, MA4.62MShares$234 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$229 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.41MShares$224 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.73B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...